Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 7/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12712258 | 0.90 | KDM4E (0.36) | ARKDM4ELMNAACSS2HTT | |
| SCHEMBL1259848 | 0.86 | PRSS12 (0.32) | ARKDM4ELMNAACSS2HTT | |
| SCHEMBL1258282 | 0.86 | ACSS2 (0.44) | ARKDM4ELMNAACSS2DCTPP1 | |
| SCHEMBL1260398 | 0.83 | ACSS2 (0.41) | KDM4ELMNAACSS2RHEBGAA | |
| SCHEMBL1258368 | 0.82 | ACSS2 (0.36) | KDM4ELMNAACSS2HTTALOX15 | |
| SCHEMBL1258277 | 0.75 | ACSS2 (0.40) | ARKDM4ELMNAACSS2DCTPP1 | |
| SCHEMBL1259198 | 0.73 | GAA (0.39) | LMNAACSS2GAA | |
| SCHEMBL1258467 | 0.73 | ACSS2 (0.36) | KDM4ELMNAACSS2SMN1; SMN2 | |
| SCHEMBL15943473 | 0.73 | KDM4E (0.38) | ARKDM4ELMNAACSS2DCTPP1 | |
| SCHEMBL1260127 | 0.69 | KMT2A (0.51) | ACSS2RHEBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8586616-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8586616-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-19 | — | — | US | disclosed |
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2011-04-14 | — | — | US | disclosed |
| US-7879895-B2 | prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-7879895-B2 | prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-7879895-B2 | prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2010-11-25 | — | — | US | disclosed |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | NG RAYMOND | 2008-05-22 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| EP-1812406-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1805147-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-25 | — | — | US | disclosed |
| WO-2006039215-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006039243-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | AR 1/4885KDM4E 1086/4885LMNA 3422/4885 |
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | AR 1/4885KDM4E 1086/4885LMNA 3422/4885 |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | AR, NR5A1, ESRRA | AR 1/4885KDM4E 1086/4885LMNA 3422/4885 |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | AR, FSHR, BRDT | AR 1/4885KDM4E 528/4885LMNA 4079/4885 |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | AR, NR5A1, ESRRA | AR 1/4885KDM4E 1086/4885LMNA 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.